DVA

Business Context and Reporting Period

Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2004
Business Overview: DaVita is a leading provider of dialysis services. The company operates a network of dialysis centers and provides related laboratory and pharmaceutical services. Approximately 50% of revenues are derived from Medicare, 42% from private payors, and the remainder from Medicaid and other sources.

Key Financial Metrics

Note: Figures in millions unless otherwise noted. Q1 2003 debt figures are derived from Note 3 for the comparable period.

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased 16% year-over-year to $535.4 million. This was driven by a 10% increase in dialysis treatment volume and a 5% increase in average reimbursement rates per treatment.
• Profitability: Net income rose 45% to $52.9 million, aided by a significant reduction in debt expense ($11.6 million vs. $19.5 million in Q1 2003) due to debt restructuring and lower interest rates.
• One-Time Items: The quarter included $19 million in recoveries of prior-period Medicare laboratory services (received in cash during Q1 2004), which boosted operating cash flow and other income.
• Cost Structure: Patient care costs remained stable at 68% of revenues. General and administrative expenses increased 16% year-over-year due to higher labor and benefit costs.
• Liquidity: Cash and cash equivalents increased by $91.5 million during the quarter, primarily due to strong operating cash flows and the receipt of the $19 million lab recovery, offset by capital expenditures and acquisitions.

Guidance, Outlook, and Risks

Outlook and Guidance

• 2004 Operating Income Target: Management targets full-year 2004 operating income between $370 million and $390 million.
• Long-Term Growth: The company maintains a three-year outlook of an average annual operating income increase of 3% to 8% on a cumulative basis.
• Volume Growth: Non-acquired annual growth rates are expected to remain in the 3.0% to 5.0% range for 2004.

Risks and Contingencies

• Government Investigations: The company is cooperating with the U.S. Attorney's Office and the HHS Office of Inspector General regarding a review of historical billing practices, financial relationships with physicians, and pharmaceutical services. Penalties could be substantial if wrongdoing is found.
• Medicare Lab Review: A Florida-based laboratory subsidiary is under ongoing review. While $19 million was recovered in Q1 2004, approximately $11 million in claims remain under appeal with no assurance of recovery.
• Reimbursement Rates: Approximately 42% of revenue comes from private payors, which are under pressure to reduce rates. Additionally, Medicare reimbursement rates for dialysis have not increased since 2001, creating inflationary cost pressures.
• Pharmaceutical Costs: EPO (Erythropoietin) administration accounts for roughly one-third of revenues. The company faces risks from price increases by the sole supplier (Amgen) and potential changes in clinical practice patterns or reimbursement rules.

Investor Verification Checklist

• Debt Restructuring Impact: Verify the sustainability of the reduced debt expense ($7.8 million decrease YoY) and the terms of the interest rate swaps fixing rates at 3.69% effective.
• Lab Recovery Sustainability: Confirm the status of the remaining $11 million in appealed Medicare lab claims and the likelihood of future recoveries.
• Private Payor Mix: Monitor the percentage of revenue from private payors (currently 42%) and any trends in rate negotiations or patient mix shifts toward lower-paying government plans.
• Regulatory Exposure: Track developments in the U.S. Attorney's Office and OIG investigations regarding billing and physician relationships.
• Operating Cash Flow Quality: Assess operating cash flow excluding the $19 million one-time lab recovery to gauge core business liquidity.